Breast Cancer Clinical Trial
Official title:
A Randomized Controlled Comparison of PECI/SPB Versus Intercostal Nerve Block for the Management of Postoperative Pain in Latissimus Dorsi Flap Reconstruction
Regional Anesthesia is a procedure in which numbing medication is injected around nerves
that transmit pain from areas involved in a surgery. The objective is to block the nerves so
a patient does not feel pain after surgery. Regional nerve blocks offer many advantages over
traditional anesthetic techniques, including faster recovery time, fewer side effects and a
dramatic reduction in post-surgical pain.
The use of regional anesthesia in breast reconstructive surgery, such as the latissimus
dorsi flap, has led to major improvements in patient care. Today, the most common regional
anesthetic used in latissimus dorsi flap reconstruction is the intercostal nerve block,
where numbing medication is injected around the nerves supplying the chest wall.
While intercostal nerve blocks have been used successfully in breast surgery, they do not
provide a complete nerve block to the chest wall, as there are some nerves that are
unaccounted for in the block which can contribute to a patients pain after surgery.
The mixed pectoral one / serratus plane block (PECI/SPB) block is another regional nerve
block that has been successfully used by anesthesiologists at The Ottawa Hospital and offers
a more complete pain blockade than the intercostal nerve block, as it includes more nerves
that supply the breast. In addition to this, the intercostal nerve block is a so-called
"blind-technique" compared to the PECI/SPB block, which is more accurately guided by
ultrasound. Blind techniques are associated with higher failure rates.
Both the intercostal nerve block and the PECI/SPB nerve block have been used successfully at
the Ottawa Hospital. In this study, the investigators propose a prospective, double blinded,
randomized controlled, head to head comparison of the PECI/SPB and intercostal nerve block
to determine which block is associated with the best pain blockade and patient satisfaction
in lattissimus dorsi flap surgery.
| Status | Not yet recruiting |
| Enrollment | 42 |
| Est. completion date | June 2017 |
| Est. primary completion date | June 2017 |
| Accepts healthy volunteers | No |
| Gender | Female |
| Age group | 18 Years and older |
| Eligibility |
Inclusion Criteria: - Breast Reconstruction using the Latissimus Dorsi Flap Exclusion Criteria: - All patients undergoing breast reconstruction using techniques other than the pedicled latissimus dorsi myocutaneous flap - Preexisting diagnosis of a chronic pain disorder - BMI > or = to 35/kg/m2 - History of allergy or sensitivity to local anesthetic - History of coagulopathy or bleeding disorder - Weight <50Kg - Allergies to local anesthetic, celecoxib, acetaminophen, hydromorphone |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care
| Country | Name | City | State |
|---|---|---|---|
| n/a | |||
| Lead Sponsor | Collaborator |
|---|---|
| Ottawa Hospital Research Institute |
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Total 24 Hour Narcotic Usage | This is the most common primary outcome used in the regional anesthesia literature when comparing nerve blocks. | 24 hours | No |
| Secondary | Time to first analgesic request (TFA) | 24 hours | No | |
| Secondary | Postoperative Pain score at 0h, 1h, 3h, 5h, 24 hours | 24 hours | No | |
| Secondary | Patient self reported pain score at 24 hours post-surgery | 24 hours | No | |
| Secondary | Peak expiratory flow rate | 24 hours | No | |
| Secondary | Breast Q Questionnaire | Physical and Psychological well-being questionnaire after breast reconstruction | 24 hours | No |
| Secondary | QoR-40 Patient Satisfaction Questionnaire | Perioperative Care Satisfaction Questionnaire | 24 hours | No |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
| Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
| Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
| Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
| Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
| Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
| Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
| Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
| Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
| Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
| Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
| Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
| Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
| Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
| Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
| Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
| Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
| Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A |